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Temporal and spatial control of gene expression can be achieved using an inducible
system as a fundamental tool for regulated transcription in basic, applied and eventually
in clinical research. We describe a novel “hit and run” inducible direct reprogramming
approach. In a single step, 2 days post-transfection, transiently transfected Sox2FLAG
under the Leu3p-αIPM inducible control (iSox2) triggers the activation of endogenous
Sox2, redirecting primary astrocytes into abundant distinct nestin-positive radial glia cells.
This technique introduces a unique novel tool for safe, rapid and efficient reprogramming
amendable to regenerative medicine.
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INDUCIBLE GENE EXPRESSION SYSTEMS
From the time of the first transcriptional regulatory systems (Gossen and Bujard, 1992), several
inducible gene expression systems were developed (Clackson, 1997; Saez et al., 1997; Rossi and Blau,
1998) for applications in gene function analysis (Malleret et al., 2001), drug discovery (Aubel et al.,
2001), gene therapy (Auricchio et al., 2002), engineering of desired phenotypes during development
and in adult life (Niwa et al., 2000), trangenesis (Rossant and Nagy, 1995), stem cell programming
and reprogramming (Brambrink et al., 2008; Hockemeyer et al., 2008; Maherali et al., 2008;
Stadtfeld et al., 2008, 2010; Welstead et al., 2008; Wernig et al., 2008; Markoulaki et al., 2009; Carey
et al., 2010). Regulatory systems developed to control the temporal and spatial gene expression use
mostly fusion proteins as regulators and hormones or antibiotics as signals for gene expression. In
mammals, the most commonly used inducible systems include the tetracycline system (Sprengel
and Hasan, 2007), the systems of the recombination enzymes Cre/loxP (Sauer, 1998) and
Flipase/FRT (Hummel and Klämbt, 2008), and the CRE-ERT2 system based on the function and
modularity of the ligand-binding domain of the estrogen receptor (ER)(Chiba et al., 2000). The
“OFF/ON” gene switches allow for the expression of dominant negative and cytotoxic proteins
(Angrand et al., 1998), for the reversibility of the target gene expression (Kistner et al., 1996),
for the study of “loss or gain” of function phenotypes (Caulin et al., 2007) and for the isolation
of functional components (Meissner et al., 2003). The limitations of these systems lie within the
fact that antibiotics are used as regulators of gene expression, resulting in cytotoxicity, interference
with embryonic development, the high cost of the inducer, leakiness, chromosomal alterations,
immune response and incompatibility in the integration into the regulatory andmetabolic network
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of the target cell (Danielian et al., 1998; Gao et al., 1999; Loonstra
et al., 2001; Wunderlich et al., 2001). Thus, tighter control of
gene induction with no side effects is fundamental for gene
function analysis, for the development of animal models and
most importantly for the development of novel approaches in
gene and stem cell therapy.
LEU3P-α-IPM INDUCIBLE GENE
EXPRESSION
We have previously reported a novel heterologous ligand-
inducible regulatory “OFF-ON” genetic switch, based on the
yeast transcription factor Leu3p (Leu3p-α-IPM; Poulou et al.,
2010). This system is based on a transcription factor (Leu3p)
involved in the regulation of the leucine pathway in yeast,
whose function is controlled by α-IPM, a metabolite involved
in leucine biosynthesis itself (Kohlhaw, 2003). Leu3p acts as an
active repressor binding to its UASLEUDNA element, turning
into an activator of the transcription in the presence α-IPM
(Sze et al., 1992), an ideal inducer since it exhibits lipid
solubility, metabolic stability, rapid “OFF-ON” kinetics with
no apparent toxicity to mammalian cells, to fertilized mouse
eggs cultured ex vivo and to animals alike (Poulou et al.,
2010). Although the leucine biosynthetic pathway is found
only in prokaryotes, fungi and plants, Leu3p has been shown
to be fully functional In mammalian cells in culture (Sze
and Kohlhaw, 1993; Remboutsika, 1994; Guo and Kohlhaw,
1996) and in primary mouse embryonic fibroblasts isolated
from double transgenic mouse embryos bearing ubiquitously
expressing Leu3p and a Leu3p regulated GFP reporter (Poulou
et al., 2010). This system would be ideal for use in stem cell
programming and reprogramming strategies transferable from
the bench to the clinic.
PRESENT STUDY
Here, we show for the first time that the Leu3p-α-IPM inducible
system can be used in direct reprogramming experiments.
AIM
To directly reprogram astrocytes to neural stem cells by “hit and
run” Leu3p-α-IPM inducible Sox2 expression approach.
METHODS
Experimental Animals
Sox2COIN/+ mice were bred with Tg(hGFAP:CRE) mice (Zhuo
et al., 2001) to generate Sox2RG−INV/+ mice harboring an
ablation of Sox2 function in radial glia cells. All animals were
handled in strict accordance with good animal practice as defined
by the Animals Act 160/03.05.1991 applicable in Greece, revised
according to the 86/609/EEC/24.11.1986 EU directive regarding
the proper care and use of laboratory animals and in accordance
to the Hellenic License for Animal Experimentation at the
BSRC” Alexander Fleming” (Prot. No. 767/28.02.07) issued after
protocol approval by the Animal Research Committee of the
BSRC “Alexander Fleming” (Prot. No. 2762/03.08.05).
Primary Astrocyte Culture
Brains were carefully dissected from P3 mouse pups, the
meninges were removed and the remaining brain tissue was
digested with 0025% trypsin in CaMg-free HBSS. The tissue was
pipetted up and down with a 10 ml pipette to generate a single
cell suspension, shaken for 10 min at 37◦C on a rotary shaker, in
a waterbath (5 ml per brain). At the end of the incubation time, 5
ml of DMEM containing 10% FBS were added, the sample was
pipetted a few times with a 10 ml pipette and passed through
a 70 µm nylon mesh to remove the debris. After centrifugation
at 200 g for 10 min, the cell pellet was washed once in complete
media before the cells were re-suspended in 7ml complete media,
plated out in T 25 cm plates coated poly-L lysine (100 mg/ml).
The astrocytes were allowed to grow to confluency (∼10–12
days) with media changes every 3 to 5 days. P3 astrocytes were
cultured at a density of 2 × 104 cells/cm2 in 4 well Sonic
Shield culture dishes (Nunc-Thermo Fisher Scientific, Roskilde,
Denmark). Transfection was performed using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions.
α-IPM (20 mM final concentration) was added to the culture
media 1 day post-transfection. Cells were incubated for another
24 h, rinsed with 1 × PBS, fixed in 4% ice-cold PFA in 0.12
M PB for 10 min on ice, rinsed again with 1 × PBS multiple
times, before use for immunofluorescence or mounting in 50%
glycerol before phase contrast photography on a Leica DMI3000
microscope.
RT-PCR
Total RNA was isolated using TriZol, according to the supplier’s
instructions, (Invitrogen) and RT-PCR was carried out using
the Qiagen One-Step RT-PCR system. The following primers
were used: for Gapdh (T = 57◦C): 5′-CATCTCTGCCCCCTC
TGCTG-3′ (forward) and 5′-CGACGCCTGCTTCACCACCT-
3′ (reverse); for endoSox2 (T = 62◦C): 5′- CCCCCGGCGGCA
ATAGCA -3′ (forward) and 5′-TCGGCGCCGGGGAGATAC
AT-3′ (reverse); for Sox2FLAG (T= 60◦C): 5′-CCCCCGGCGGCA
ATAGCA-3 (forward) and 5′-TCAAAGCTTGTCATCGTCGTC
CTT-3′ (reverse); for wnt3a (T = 52◦C) 5′- ATTGAATTTGGA
GGAATGGT-3′ (forward) and 5′- CTTGAAGTACGTGTAACG
TG-3′ (reverse); for nestin (T = 60◦C) 5′- CGCTGGAACAGA
GATTGGAAGG-3′ (forward) and 5′ –GTCTCAAGGGTATTA
GGCAAG- 3′ (reverse).
Immunohistochemistry
Cells and cortical sections were fixed in 4% PFA in 0.12 M
PB, pH 7.2 at 4◦C for 5 min and incubated in Blocking
buffer (BB; 0.12 M PB, pH 7.2, 0.15% glycine, 2 mg/ml BSA
fragment V (Gibco-Invitrogen) and 0.1% Triton X-100) for
1 h on ice. Cells were incubated o/n at 4◦C with primary
antibodies in BB. After extensive washes with PBS at RT, cells
were incubated with species specific secondary antibodies (Alexa
488-conjugated, 1:500; Invitrogen) for 1 h at RT. Samples were
mounted in anti-fade DAPI mounting media (Invitrogen) and
photographed on a Leica SP5 confocal microscope. Primary
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FIGURE 1 | Leu3p-α-IPM inducible fast - track direct reprogramming of astrocytes to neural stem cells. (A) Leu3p·α-IPM mode of action: Transcriptional
repressor upon binding to the UASLEU DNA element and transcriptional activator upon α-IPM ligand binding. (B) Superimposed bright field and confocal images of
transiently transfected primary P3 murine astrocytes (i-iv) with either Leu3p protein (L3) (ii) or UASLEU-eGFP reporter (eL3R) (iii) or both L3/eL3R (iv). eGFP is observed
only in cells UASLEU with both L3/eL3R (iv). Scale bar 75 µm. (C) Generation iSox2 expression system under the control of Leu3p UASLEU elements. (D) iSox2
induces endogenous Sox2, nestin, and wnt3a 48 h post-transfection in P3 primary murine astrocytes. (E) Sox2+ and RC2+ neural progenitors in the proliferating
zone of E14 cortex of wild type mouse embryos. eGFP expression detected in the proliferating zone of E14 cortex after Sox2 ablation in ragial glia cells. Scale bar 75
µm. (F) Sox2 is not expressed in GFAP+ cells in the proliferating zone of P3 mouse cortex. Scale bar 50 µm. (G) iSox2(v-viii) reduces the astrocytic marker GFAP (i,-ii,
iv–vi) in P3 primary murine astrocytes and induces a Nestin+ (vii) radial glia (RC2+) (viii) NSC phenotype 48 h post-transfection. Dapi staining of nuclei is present in the
upper right corner in all panels. Scale bars for panels i and v represent 250 µm and for panels ii-iv and vi-viii represent 75 µm. (H) Graphs depicting the GFAP+ and
either nestin+ or RC2+ cells in untransfected astrocytes and in reprogrammed cultures.
antibodies: anti-Nestin (mouse IgG 1:75, Developmental Studies
Hybridoma Bank (DSHB), University of Iowa, http://dshb.
biology.uiowa.edu), anti-RC2 (mouse IgM 1:100, DSHB), anti-
GFAP, Cy3-linked (mouse IgG 1:100, SIGMA), anti-Sox2 (rabbit
IgG 1:1000, Santa Cruz, INC).
RESULTS AND DISCUSSION
Nervous stem repair is an enormous challenge to regenerative
medicine. Even though, neural stem/progenitor cells (NSCs)
can be generated as an intermediate cell type from astrocytes
on their way to generate neurons in vivo and in vitro,
limitations including viral infection and integration, as well
as uncontrolled reactivation of transgenes hamper their use in
clinical applications (Tomanin and Scarpa, 2004; Huang and
Tan, 2015). Here, we investigated the efficiency of the Leu3p-
α-IPM as a “hit and run” gene switch to generate NSCs from
astrocytes in vitro. We first demonstrated that α-IPM addition
efficiently induced a Leu3p regulated eGFP reporter in transiently
transfected primary astrocytes (Figures 1A,Bi–iv). NSCs develop
and maintain their properties under the guidance of Sox2
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(Ferri et al., 2004; Remboutsika et al., 2011; Mandalos et al.,
2014; Figure 1E) and they can be generated by direct lineage
reprogramming of astrocytes via in vivo overexpression of Sox2
(Niu et al., 2013). We then designed an iSox2 Leu3p inducible
system to test the rapidness and efficiency in imposing Sox2
reprogramming ability to primary astrocytes ex vivo (Figure 1C).
Although, in vivo at P3 astrocytes do not appear to express Sox2
(Niu et al., 2013; Figure 1F), in primary astrocyte cultures Sox2
(Figure 1D) and Sox2 protein (Figure 1Gi–iv) are expressed
in low levels. Astrocytes do not express Nestin (0.6 ± 0.1%)
or RC2 (0.5 ± 0.1%), markers of NSCs with a radial glia
character (Figure 1D,Gi–iv). Two days post-transfection, high
levels of Nestin (85 ± 13.89%) and RC2 (93 ± 6.97%) are
expressed only in cells after Sox2 induction (iSox2) in astrocyte
cultures (Figures 1D,Gv-viii,H). Concurrently, GFAP+ cells are
reduced in iSox2 cultures (24.8 ± 21.73%; Figures 1Gv-viii,H),
respectively, when these are compared to control astrocyte
cultures (83.28± 10.43%; Figures 1Gi-viii,H). One would expect
that only the cells with the highest expression of Sox2 could revert
the astrocytic (GFAP+) to a NSC (Nestin+, RC2+) radial glia
phenotype. However, we observed that the majority of cells have
acquired a Nestin+ phenotype. This led us to believe that the
iSox2 cells now express a signaling molecule that controls NSC
identity. One of these could be wnt3a, known to be involved in
the proliferation of NSCs (Lie et al., 2005), but also expressed
in low levels in untransfected astrocytes cultures (Figure 1D).
Indeed, wnt3a was induced in iSox2 NSCs, along with the
induction of endogenous Sox2 and nestin (Figure 1D). Thus,
iSox2 can generate NSCs from astrocytes rapidly and efficiently
in vitro.
To build an ideal regulatory system for clinical research
three factors are important (a) activation by a highly specialized
non-toxic bio-available exogenous ligand, (b) inactivation in
the absence or removal of the ligand, and (c) no interference
with endogenous mammalian gene expression and metabolic
pathways. Evidently, Leu3p-α-IPM represents this novel unique
tool for simple, safe, fast and efficient inducible programming
and reprogramming in different cell types for gene and stem cell
strategies directly amendable to the clinic.
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